![]() |
市场调查报告书
商品编码
1433295
全球 GMP 测试服务市场 2023-2030Global GMP Testing Service Market 2023-2030 |
全球 GMP 测试服务市场预计在预测期内(2023-2030 年)将以 6.7% 的CAGR成长。市场的成长归因于医疗保健预防性维护的不断增长。 GMP 计划是一种预防性医疗保健,重点是早期发现儿童生长问题。 GMP 测试的要求源于确保下一代健康和福祉的优先考虑。根据美国国立卫生研究院的数据,世界卫生组织 (WHO) 2023 年 5 月估计有 1.49 亿五岁以下儿童生长发育迟缓,约 4,540 万名儿童消瘦。如果不加以解决,儿童营养不良可能会对身体和智力发展产生不利影响、增加疾病风险、降低体力和工作生产力、失业以及更高的贫穷风险,并可能影响子孙后代。为了解决这个问题,联合国儿童基金会(WHO)建议实施生长监测和促进(GMP)计画。
此外,生长监测和促进 (GMP) 包括定期追踪儿童的体重和身高,并采取行动解决任何已发现的健康问题。该计画自 20 世纪 80 年代开始实施,旨在识别儿童的健康和营养问题;促进母乳哺育和适当的补充餵食;提高儿童保健服务的使用率。
Global GMP Testing Service Market Size, Share & Trends Analysis Report by Technology (Single Stage and Double Stage), by Absorber Type (Lithium Bromide and Ammonia), by Power Source (Direct Fired, Indirect Fired, and Water Driven), and by Application (Chemicals, Food & Beverages, Power, Paper & Pulp, power & energy and Others), Forecast Period (2023-2030)
The global GMP testing service market is anticipated to grow at a CAGR of 6.7 % during the forecast period (2023-2030). The market's growth is attributed to growing healthcare preventive maintenance. GMP programs are a type of preventive healthcare that focuses on the early detection of growth problems in children. The requirement for GMP testing stems from the priority of ensuring the health and well-being of the next generation. According to the National Institute of Health, in May 2023, World Health Organization (WHO), an estimated 149 million children below the age of five years are affected by stunted growth and approximately 45.4 million children experience wasting. If left unaddressed, childhood malnutrition can lead to adverse effects on physical and intellectual development, an increased risk of diseases, reduced physical strength and work productivity, unemployment, and a higher risk of poverty that can extend to future generations. To tackle this issue, the United Nations Children's Fund (WHO) recommends the growth monitoring and promotion (GMP) program.
Furthermore, Growth monitoring and promotion (GMP) involves regularly tracking a child's weight and height, and taking actions to address any identified health issues. It has been implemented since the 1980s with the aims of identifying health and nutritional problems in children; promoting breastfeeding and appropriate complementary feeding; and increasing the utilization of child health services.
The global GMP testing service market is segmented on the service type, service provider, and end-user. Based on the service type, the market is sub-segmented into packaging and shelf-life testing,
product validation testing, bioanalytical services, and others. Based on the service provider, the market is sub-segmented into in-house testing facilities, and outsourced facility. Further, on the basis of end-user, the market is sub-segmented into pharmaceutical and biopharmaceutical companies, medical device companies, and others. The product validation testing subcategory is expected to capture a significant portion of the market share within the service type segment. This is attributed to the rise in demand for higher-quality and safe administration of service.
Among the end-user, the pharmaceutical and biopharmaceutical companies sub-segment is expected to hold a considerable share of the global GMP Testing Service market. The segmental growth is attributed to the growing integration of pharmacies. Medication management and administration are increasingly being handled by pharmacies and hospitals. On-site 3D printing can help healthcare facilities offer a more extensive and customized variety of therapies by streamlining the creation of personalized pharmaceuticals. For instance, in October 2023, CurifyLabs has launched GMP Pharma Inks for On-Site 3D Printing of Personalized medicines in pharmacies and hospitals. The pharmaceutical industry is recognizing the value in considering individual variation when prescribing medications, such as differences in genetics, age, gender, allergies, and disabilities.
The global GMP testing service market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of significant biopharmaceutical and pharmaceutical corporations in the countries such as the US. Furthermore, the increased frequency of substantial pharmaceutical businesses and their research and development operations drives the region's demand for GMP testing.
Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising concerns regarding public health. Poor-quality pharmaceuticals can impair public health by causing treatment failure, increasing drug resistance, and patient injury. This apprehension is a major motivator for the adoption of GMP standards and testing services. According to the BMC, in April 2022, World Health Organization (WHO), a significant portion of medicines available in low-income countries (LICs) and in Asia have been confirmed to be of poor quality. Up to 13.7% of medicines available in Asia have been reported to be of poor quality, and in more than one-third of countries, drug regulatory systems are either absent or lack stringent protocols. This poses a challenge to global health, as poor quality or substandard medicines can impede effective treatment, increase antimicrobial resistance, and create a socioeconomic burden.
Furthermore, the Afghan pharmaceutical sector is one of the least developed globally, with domestic manufacturers only meeting 5% of total pharmaceutical demand. The remaining 95% is imported from countries including Pakistan, China, India, Iran, United Arab Emirates (UAE), and Turkey. WHO has developed Good Manufacturing Guideline (GMP) standards to ensure consistent production of quality products. It is estimated that about one billion dollars of pharmaceuticals are smuggled into Afghanistan annually.
The major companies serving the GMP testing service market include includes Labcorp, Merck KGaA, Microchem Laboratories, North American Science Associates, LLC, Pace Analytical Services, LLC and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2022,GenScript USA Inc. launched the availability of new GMP-grade GenExact single-stranded DNA (ssDNA) and GenWand closed-end linear double-stranded DNA (dsDNA) services. The services provided enable next-generation gene and cell therapy R&D programs to proceed faster and more efficiently to IND filing and clinical trials.